Prognostic Significance of Cereblon Expression in Patients With Multiple Myeloma
| Autor: | Milica Radojkovic, Mila Puric, Goran Trajkovic, Irena Glumac, Zoran Milojevic, Natasa Tosic, Darko Antic, Marija Dencic Fekete, Jelena Bila, Olivera Markovic, Milena Todorovic Balint, Biljana Mihaljevic, Jelena Jelicic, Sonja Pavlovic, Aleksandra Sretenovic |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
Oncology
Adult Male Cancer Research medicine.medical_specialty Ubiquitin-Protein Ligases Gene Expression Kaplan-Meier Estimate 03 medical and health sciences 0302 clinical medicine Autologous stem-cell transplantation Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Distribution (pharmacology) Humans In patient Multiple myeloma Adaptor Proteins Signal Transducing Aged Neoplasm Staging Aged 80 and over Bortezomib Proportional hazards model business.industry Cereblon Hematology Middle Aged medicine.disease Prognosis 3. Good health Thalidomide Treatment Outcome 030220 oncology & carcinogenesis Immunology Female business Multiple Myeloma 030215 immunology medicine.drug Peptide Hydrolases |
| Zdroj: | Clinical lymphoma, myelomaleukemia. 16(11) |
| ISSN: | 2152-2669 |
| Popis: | Background To personalize the treatment approach for patients with multiple myeloma (MM), molecular markers such as cereblon ( CRBN ) are currently the focus of investigation. The aim of the present study was to test the prognostic significance of CRBN expression in MM patients ineligible for autologous stem cell transplantation (ASCT). Patients and Methods The data from 92 previously untreated patients were analyzed. The distribution according to the International Staging System score was 26.1%, 30.4%, and 43.5% with a score of 1, 2, and 3, respectively. Thalidomide- and bortezomib-based combinations were used in 83.7% and 16.3% of the patients, respectively. Results A treatment response (complete remission, very good partial remission, partial remission) was achieved in 83.7% of the patients and correlated with high CRBN expression ( P = .006), mainly in the patients treated with thalidomide ( P = .028). Low CRBN expression affected progression-free survival (PFS; P = .017) but not overall survival (OS) in patients treated with thalidomide and had no influence on OS in the bortezomib group. In the Cox regression model, low CRBN expression was the most important prognostic parameter that influenced PFS in the thalidomide-treated patients ( P = .012). Conclusion CRBN expression is of prognostic value in MM patients ineligible for ASCT treated with thalidomide as an immunomodulatory drug. With low expression indicating a possible suboptimal treatment outcome, measurement of CRBN expression might serve as additional prognostic tool in the personalized treatment approach. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect